Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 multi-center double-blind randomized crossover study of the efficacy safety and tolerability of fixed combination torcetrapib (Cp-529 414)/atorvastatin, compared with atorvastatin therapy alone, and fenofibrate alone, in subjects with Fredrickson type III hyperlipoproteinemia (familial dysbetalipoproteinemia).

Next Previous
Trial Profile

Phase 3 multi-center double-blind randomized crossover study of the efficacy safety and tolerability of fixed combination torcetrapib (Cp-529 414)/atorvastatin, compared with atorvastatin therapy alone, and fenofibrate alone, in subjects with Fredrickson type III hyperlipoproteinemia (familial dysbetalipoproteinemia).

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atorvastatin; Fenofibrate; Torcetrapib/atorvastatin
  • Indications Hyperlipoproteinaemia type III
  • Focus Biomarker; Registrational; Therapeutic Use

Most Recent Events

  • 16 Feb 2012 Actual patient number is 41 according to ClinicalTrials.gov.
  • 05 Dec 2006 Status change
  • 20 Nov 2005 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top